SCHEMBL3800520

SCHEMBL3800520

CNC(=O)c1ccc(NC(=O)c2cc(F)cc(-c3cn4ccnc4c(Nc4ccc(OC)c(OC)c4)n3)c2)cc1

nearest known ligand 0.73

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SYK P43405 20/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3803885 0.92 SYK (0.74) SYK
SCHEMBL3808294 0.90 SYK (0.90) SYK
SCHEMBL3804879 0.88 SYK (0.74) SYK
SCHEMBL3792907 0.88 SYK (0.76) SYK
SCHEMBL3785147 0.87 SYK (0.79) SYK
SCHEMBL3803202 0.86 SYK (0.78) SYK
SCHEMBL3805099 0.86 SYK (0.85) SYK
SCHEMBL3789826 0.85 SYK (0.81) SYK
SCHEMBL3784267 0.85 SYK (0.81) SYK
SCHEMBL4326602 0.85 SYK (0.86) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2252617-A1 6-ARYL-IMIDAZ0[L, 2-A]PYRAZINE DERIVATIVES, METHOD OF MAKING, AND METHOD OF USE THEREOF CGI Pharmaceuticals, Inc. (US) 2010-11-24 EP claimed
US-20090221612-A1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF Kronos Bio, Inc. 2009-09-03 US claimed
WO-2009102468-A1 6-ARYL-IMIDAZ0[L, 2-A] PYRAZINE DERIVATIVES, METHOD OF MAKING, AND METHOD OF USE THEREOF CGI PHARMACEUTICALS, INC. (US) 2009-08-20 WO claimed
US-8697699-B2 Imidazopyrazine SYK inhibitors GILEAD CONNECTICUT, INC. (US) 2014-04-15 US disclosed
US-20130023499-A1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF GILEAD CONNECTICUT, INC. (US) 2013-01-24 US disclosed
US-20130023499-A1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF GILEAD CONNECTICUT, INC. (US) 2013-01-24 US disclosed
US-20130023499-A1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF GILEAD CONNECTICUT, INC. (US) 2013-01-24 US disclosed
EP-2252617-A1 6-ARYL-IMIDAZ0[L, 2-A]PYRAZINE DERIVATIVES, METHOD OF MAKING, AND METHOD OF USE THEREOF CGI Pharmaceuticals, Inc. (US) 2010-11-24 EP disclosed
US-20090221612-A1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF Kronos Bio, Inc. 2009-09-03 US disclosed
US-20090221612-A1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF Kronos Bio, Inc. 2009-09-03 US disclosed
WO-2009102468-A1 6-ARYL-IMIDAZ0[L, 2-A] PYRAZINE DERIVATIVES, METHOD OF MAKING, AND METHOD OF USE THEREOF CGI PHARMACEUTICALS, INC. (US) 2009-08-20 WO disclosed
WO-2009102468-A1 6-ARYL-IMIDAZ0[L, 2-A] PYRAZINE DERIVATIVES, METHOD OF MAKING, AND METHOD OF USE THEREOF CGI PHARMACEUTICALS, INC. (US) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023499-A1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF SYK, MYD88, BTK SYK 1/4885
US-20090221612-A1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF SYK, MYD88, BTK SYK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.